ArticleUpdates in surgery2025
Development and risk stratification of a prognostic nomogram for hepatoblastoma: analysis of the SEER database.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoblastoma, the most common primary liver malignancy in children, exhibits significant clinical and biological heterogeneity, leading to varying prognoses. This study aimed to identify independent prognostic factors for overall survival in pediatric hepatoblastoma patients, develop and validate a nomogram prediction model, and establish a risk stratification system. We conducted a retrospective analysis of patients aged ≤18 years with hepatoblastoma using data from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2020). Univariate and multivariate Cox regression analyses identified age, race, tumor stage, tumor size, surgery, and chemotherapy as independent prognostic factors. We developed a nomogram prediction model based on these factors, which underwent internal and external validation. The model accurately predicts 1-, 3-, and 5-year overall survival rates. We also established a risk classification system that stratifies patients into low, intermediate, and high-risk groups. Subgroup analysis revealed that low-risk patients had better survival outcomes with hepatectomy, while intermediate-risk patients benefited more from liver transplantation. The developed nomogram enables individualized prediction of overall survival rates in pediatric hepatoblastoma patients, and the risk stratification system can guide early and accurate prognostic assessment.
Indexed as
Identifiers
40048092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.